IDegAsp: A novel soluble insulin analogs combination

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1533-1540

  Ma, Zhulin ^a   Parkner, Tina ^a   Christiansen, Jens Sandahl ^a   Laursen, Torben ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetes mellitus; Insulin analog; Insulin degludec; Premixed insulin

Indexed keywords

IDEGASP; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DEGLUDEC PLUS INSULIN ASPART; INSULIN GLARGINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; LONG ACTING INSULIN;

ANTIDIABETIC ACTIVITY; CLINICAL STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MOLECULAR SEQUENCE DATA;

EID: 84867290830     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.722203     Document Type: Review

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of ong-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
3. American Diabetes Association et al. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61
4. American Diabetes Association. Insulin administration. Diabetes Care 1998;21(Suppl 1):572-5
5. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-5
6. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83
7. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15
8. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008;47:7-20
9. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333-49
10. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011;13(Suppl 1):S5-14
11. Werner H, Weinstein D, Yehezkel E, Laron Z. Controversies in the use of insulin analogues. Expert Opin Biol Ther 2011;11:199-209
12. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation(abstract). Diabetes 2010;59(Suppl 1):A11
13. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29(8):2104-14
14. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-59
15. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec: multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin. Diabetologia 2010;53:S388
16. Heise T, Hovelmann U, Nosek L, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia 2011;54:S425
17. Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation(Abstract). J Pept Sci 2010;16:32
18. Hirsch IB, Franek E, Courreges JP, et al. Efficacy and safety of a new basal insulin with a bolus boost (IDegAsp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes (Abstract 1064-P). Diabetes 2011;60(Suppl 1):A292
19. Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012;167:287-94
20. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011;34:669-74
21. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009;53:298-304
22. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
23. Heller SR, Pieber T, Korsatko S, et al. A higher counter-regulatory hormone response is seen with insulin degludec than insulin glargine in response to induced hypoglycaemia in type 1 diabetes. Diabetologia 2011;54:S261
24. Nishimura E, Sorensen AR, Hansen BF, et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia 2010;53:S388-9
25. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
26. Tahrani AA, Bailey CJ, Barnett AH. Insulin degludec: a new ultra-longacting insulin. Lancet 2012;379:1465-7